JP2023548083A5 - - Google Patents

Info

Publication number
JP2023548083A5
JP2023548083A5 JP2023525049A JP2023525049A JP2023548083A5 JP 2023548083 A5 JP2023548083 A5 JP 2023548083A5 JP 2023525049 A JP2023525049 A JP 2023525049A JP 2023525049 A JP2023525049 A JP 2023525049A JP 2023548083 A5 JP2023548083 A5 JP 2023548083A5
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
acid sequence
sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548083A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057197 external-priority patent/WO2022094177A1/en
Publication of JP2023548083A publication Critical patent/JP2023548083A/ja
Publication of JP2023548083A5 publication Critical patent/JP2023548083A5/ja
Pending legal-status Critical Current

Links

JP2023525049A 2020-10-30 2021-10-29 セリアックスプルー病を治療するための組成物及び方法 Pending JP2023548083A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108163P 2020-10-30 2020-10-30
US63/108,163 2020-10-30
PCT/US2021/057197 WO2022094177A1 (en) 2020-10-30 2021-10-29 Compositions and methods for treating celiac sprue disease

Publications (2)

Publication Number Publication Date
JP2023548083A JP2023548083A (ja) 2023-11-15
JP2023548083A5 true JP2023548083A5 (cg-RX-API-DMAC7.html) 2024-11-06

Family

ID=78819631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525049A Pending JP2023548083A (ja) 2020-10-30 2021-10-29 セリアックスプルー病を治療するための組成物及び方法

Country Status (12)

Country Link
US (1) US20250064903A1 (cg-RX-API-DMAC7.html)
EP (1) EP4237554A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023548083A (cg-RX-API-DMAC7.html)
KR (1) KR20230093323A (cg-RX-API-DMAC7.html)
CN (1) CN116829166A (cg-RX-API-DMAC7.html)
AR (1) AR123961A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021368118A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195929A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006731A2 (cg-RX-API-DMAC7.html)
MX (1) MX2023004807A (cg-RX-API-DMAC7.html)
TW (1) TW202233834A (cg-RX-API-DMAC7.html)
WO (1) WO2022094177A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025068987A1 (en) 2023-09-28 2025-04-03 Takeda Pharmaceutical Company Limited A method of producing a kumamolisin-as polypeptide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE440857T1 (de) * 1998-10-05 2009-09-15 Takeda Pharmaceutical Verfahren zum eliminieren von n-terminalem methionin
JP4475707B2 (ja) * 1998-10-05 2010-06-09 武田薬品工業株式会社 N末端メチオニンの除去方法
LT2718434T (lt) 2011-08-10 2018-08-10 University Of Washington Through Its Center For Commercialization Kompozicijos ir būdai, skirti celiakijos gydymui
US10266815B2 (en) * 2013-08-14 2019-04-23 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
ES2883347T3 (es) * 2014-06-16 2021-12-07 Codexis Inc Composiciones y procedimientos para atenuar y prevenir la inflamación intestinal debida a la presencia de antígenos alimentarios peptídicos en un intestino
TN2017000520A1 (en) * 2015-06-08 2019-04-12 Univ California Compositions and methods for treating celiac sprue disease
MX2019007287A (es) * 2016-12-22 2019-09-27 Ew Nutrition Gmbh Variantes de proteasas estables.

Similar Documents

Publication Publication Date Title
JP2025028857A5 (cg-RX-API-DMAC7.html)
Kiyatkin et al. Cloning and structure of cDNA encoding α‐latrotoxin from black widow spider venom
Sacco et al. The primary structure of the cytotoxin alpha-sarcin.
JP2643968B2 (ja) Kex2エンドプロテアーゼ及びその製造方法
JP2023518596A5 (cg-RX-API-DMAC7.html)
IL273439B1 (en) Fusion proteins comprising enzyme replacement therapy enzymes
KR890003802A (ko) 재조합 dna 기술에 의해 제조된 소의 췌장 트립신 억제제, 그 제조 방법, 발현 벡터 및 재조합 숙주 및 그의 제약적 용도
HUT73394A (en) Process for production of protein
CN104507489A (zh) 用于预防和治疗类风湿性关节炎的组合物
JP2015504052A5 (cg-RX-API-DMAC7.html)
JP2024532503A5 (cg-RX-API-DMAC7.html)
Harumiya et al. EBP-37, a new elastin-binding protein in human plasma: structural similarity to ficolins, transforming growth factor-β1-binding proteins
FI4034555T3 (fi) Dap10/dap12-fuusiopolypeptidit
CN105829350A (zh) 肠激酶可切割的多肽
WO2022241831A1 (zh) 多肽的制备方法
JP2024038140A5 (cg-RX-API-DMAC7.html)
CA2076320A1 (en) Process for producing peptide
JP2015510770A5 (cg-RX-API-DMAC7.html)
Ishizaki et al. Production of recombinant human glucagon in the form of a fusion protein in Escherichia coli; recovery of glucagon by sequence-specific digestion
AU2013234860B2 (en) Method of producing a recombinant peptide
JP2021514194A (ja) ブタトリプシンの変異体
WO2025179727A1 (zh) 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法
KR102174197B1 (ko) 생산성이 향상된 비독성 프로테아제
Greenwood et al. Purification and processing of cellulose‐binding domain‐alkaline phosphatase fusion proteins
WO2025179726A1 (zh) 利那洛肽可溶性中间体和利那洛肽的制备方法